Unlock stock picks and a broker-level newsfeed that powers Wall Street.
KSE - Delayed Quote KRW

Yuyu Pharma, Inc. (000227.KS)

Compare
9,580.00
+170.00
+(1.81%)
At close: April 4 at 3:30:30 PM GMT+9
Loading Chart for 000227.KS
  • Previous Close 9,410.00
  • Open 9,470.00
  • Bid 9,580.00 x --
  • Ask 10,290.00 x --
  • Day's Range 9,420.00 - 9,600.00
  • 52 Week Range 9,030.00 - 12,700.00
  • Volume 1,630
  • Avg. Volume 2,012
  • Market Cap (intraday) 34.823B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield 120.00 (1.25%)
  • Ex-Dividend Date Dec 27, 2024
  • 1y Target Est --

Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.

www.yuyu.co.kr

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 000227.KS

View More

Performance Overview: 000227.KS

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

000227.KS
0.00%
KOSPI Composite Index (^KS11)
2.75%

1-Year Return

000227.KS
14.21%
KOSPI Composite Index (^KS11)
10.09%

3-Year Return

000227.KS
52.56%
KOSPI Composite Index (^KS11)
10.61%

5-Year Return

000227.KS
20.31%
KOSPI Composite Index (^KS11)
42.89%

Compare To: 000227.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000227.KS

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.55%

  • Return on Assets (ttm)

    3.88%

  • Return on Equity (ttm)

    8.06%

  • Revenue (ttm)

    133.15B

  • Net Income Avi to Common (ttm)

    8.72B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    42.65B

  • Total Debt/Equity (mrq)

    24.91%

  • Levered Free Cash Flow (ttm)

    21.17B

Research Analysis: 000227.KS

View More

Company Insights: 000227.KS

Research Reports: 000227.KS

View More

People Also Watch